| Literature DB >> 28129778 |
Dong-Fang Meng1, Ping Xie1, Li-Xia Peng1, Rui Sun1,2, Dong-Hua Luo1,2, Qiu-Yan Chen1,2, Xing Lv1,2, Lin Wang1,2, Ming-Yuan Chen1,2, Hai-Qiang Mai1,2, Ling Guo1,2, Xiang Guo1,2, Li-Sheng Zheng1, Li Cao1, Jun-Ping Yang1, Meng-Yao Wang1,3, Yan Mei1, Yuan-Yuan Qiang1, Zi-Meng Zhang1, Jing-Ping Yun1,4, Bi-Jun Huang1, Chao-Nan Qian5,6.
Abstract
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a common malignancy in Southern China and Southeast Asia. In this study, we investigated the functional and molecular mechanisms by which CDC42-interacting protein 4 (CIP4) influences NPC.Entities:
Keywords: CIP4; EGFR/ERK/MMP-2 axis; Extracellular matrix degradation; Invadopodia formation; N-WASP; NPC
Mesh:
Substances:
Year: 2017 PMID: 28129778 PMCID: PMC5273811 DOI: 10.1186/s13046-016-0483-z
Source DB: PubMed Journal: J Exp Clin Cancer Res ISSN: 0392-9078
Fig. 1High CIP4 expression correlates with shorter overall survival and distant-metastasis-free survival in NPC patients. a Levels of CIP4 protein expression in NPC tissues are shown under high magnifications microscopy. b Kaplan-Meier analysis indicates upregulation of CIP4 was significantly associated with poorer overall survival and distant metastasis-free survival of NPC patients (p = 0.0053, p = 0.0310, respectively). c CIP4 mRNA expression in the NPC tissues and non-cancerous nasopharyngeal (NP) mucosa tissues detected by qPCR
Association between expression of CIP4 and clinicopathological characteristics in 169 NPC patients
| Clinical factor | Cases ( | CIP4 expression |
| |
|---|---|---|---|---|
| High | Low | |||
| ( | ( | |||
| Gender | ||||
| Male | 128 | 63 | 65 | 0.961 |
| Female | 41 | 20 | 21 | |
| Ages (years) | ||||
| < 45 | 79 | 39 | 40 | 0.951 |
| ≥ 45 | 90 | 44 | 46 | |
| T stage | ||||
| T1-2 | 49 | 22 | 27 | 0.484 |
| T3-4 | 120 | 61 | 59 | |
| N stage | ||||
| N0-1 | 89 | 41 | 48 | 0.404 |
| N2-3 | 80 | 42 | 38 | |
| M stage | ||||
| M0 | 160 | 75 | 85 |
|
| M1 | 9 | 8 | 1 | |
| Clinical stage | ||||
| I-II | 17 | 6 | 11 | 0.229 |
| III-IV | 152 | 77 | 75 | |
| WHO histological classification Type 2 | ||||
| Differentiated | 8 | 2 | 6 | 0.300 |
| Undifferentiated | 161 | 81 | 80 | |
| Local-regional relapse | ||||
| No | 166 | 81 | 85 | 0.975 |
| Yes | 3 | 2 | 1 | |
| Distant metastasis | ||||
| No | 156 | 73 | 83 | 0.072 |
| Yes | 13 | 10 | 3 | |
| Progression | ||||
| No | 147 | 66 | 81 |
|
| Yes | 22 | 17 | 5 | |
| Death | ||||
| No | 142 | 63 | 79 |
|
| Yes | 27 | 20 | 7 | |
Statistical significance (p < 0.05) is shown in bold and italic
Univariate and multivariate analyses of different prognostic parameters in NPC patients
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | Cl |
| HR | Cl |
| |
| OS | ||||||
| Gender | 2.763 | 0.832–9.181 | 0.097 | … | … | … |
| Age | 2.841 | 1.198–6.734 |
| 5.148 | 1.933–13.707 |
|
| T stage | 1.317 | 0.554–3.129 | 0.533 | … | … | … |
| N stage | 1.745 | 0.810–3.761 | 0.155 | … | … | … |
| M stage | 9.441 | 3.769–23.647 |
| 14.195 | 4.642–43.407 |
|
| Clinical stage | 24.271 | 0.134–4382.908 | 0.229 | … | … | … |
| CIP4 | 1.137 | 1.043–1.240 |
| 1.111 | 1.015–1.216 |
|
| DMFS | ||||||
| Gender | 4.019 | 0.523–30.911 | 0.181 | … | … | … |
| Age | 1.451 | 0.475–4.436 | 0.514 | … | … | … |
| T stage | 0.666 | 0.218–2.037 | 0.476 | … | … | … |
| N stage | 1.908 | 0.624–5.832 | 0.257 | … | … | … |
| M stage | 13.355 | 4.058–43.955 |
| 8.565 | 2.495–29.401 |
|
| Clinical stage | 23.874 | 0.011–53961.801 | 0.421 | … | … | … |
| CIP4 | 1.199 | 1.046–1.374 |
| 1.159 | 1.006–1.336 |
|
Abbreviations: OS overall survival, DMFS distant metastasis-free survival, CI confidence interval, HR hazard ratio. Statistical significance (p < 0.05) is shown in bold and italic
Fig. 2Suppression of CIP4 expression has no effect on growth in NPC cells in vitro. a Decreased expressions of CIP4 were respectively confirmed by Western blotting in CIP4-silenced 5-8F and S18 cells compared with scrambled shRNA control cells. b Cell growth rates between CIP4-silenced and scrambled shRNA control cells were compared by MTT assay. c and d The colony formation assays were performed to determine the effect of growth in CIP4 knockdown and control cells. N.S. means no significance. The data are presented as the mean ± S.D. (from triplicates)
Fig. 3Suppression of CIP4 expression inhibits the migration and invasion of highly metastatic NPC cells in vitro. a and c Silencing CIP4 could inhibit cell migration and cell invasion in 5-8F and S18 cells compared with scrambled shRNA control cells. b and d Columns, average of three independent experiments; Bars, S.D. ***P < 0.001
Fig. 4CIP4 promotes the EGF-dependent activation of N-WASP in NPC cells. a 5-8F cells were transfected with control or CIP4-siRNA and whole-cell lysates were immunoblotted for phospho-N-WASP (Y256), total N-WASP and CIP4 at 72 h after transfection. Blots were reprobed for β-actin. b NPC cells transfected with control or CIP4-siRNA were treated with EGF for 1 min, lysed and probed for phospho-N-WASp (Y256) and then reprobed for total N-WASp and CIP4. Blot is representative of three independent experiments. c densitometric quantification of immunoblot in b
Fig. 5CIP4 plays an important role in invadopodia formation in NPC cells. a and b 5-8F cells and S18 cells transfected with control or CIP4 siRNA were plated on glass-bottom dishes coated with Gelatin From Pig Skin, Oregon Green® 488 Conjugate and cultured for 20 h before being stained for endogenous CIP4 and F-actin. The cells were fixed and stained with anti-cortactin antibody (blue) and F-actin (red). The arrowheads indicate the position of extracellular matrix (ECM)-degrading invadopodia. Scale bar, 30 μm. c and d Gelatin degradation areas were counted and measured, normalized for cell number and averaged over replicates from three independent experiments. The data are expressed as the mean ± S.D. of three independent experiments. ***, P < 0.001
Fig. 6CIP4 modulates EGFR signaling and promotes MMP-2 expression in NPC cells. a and b Serum-starved 5-8F and S18 Control and KD1 cells were treated with EGF (100 ng/ml) for 0–20 min. Lysates were subjected to IB with the antibodies indicated on the right. c and d Serum-starved 5-8F and S18 Control and KD1 cells were treated with EGF (100 ng/ml) for 0–120 min. Lysates were subjected to IB with the indicated antibodies. e Densitometry was performed, and relative phospho-Erk levels are shown in the graph below (mean ± S.D.). *, P < 0.05. f IB analysis of MMP-2 and MMP-9 in 5-8F and S18 Control and KD1 cell lysates. GAPDH was used as a loading control
Fig. 7CIP4 promotes distant metastasis in vivo. a Histological image of lung metastasis in nude mice after tail vein injection of 5-8F cells. Scale bar, 500 μm. b The average wet lung weights of the mice were not difference between CIP4 KD and controls. c The numbers of lung metastases (mean ± S.D.) were counted and summarized. ***P < 0.001. d The metastasis rates of CIP4 knockdown 5-8F cells in vivo. The proportion of popliteal lymph node metastases was significantly reduced upon CIP4 silencing in 5-8F cells (n = 30 per group). P values were calculated using a chi-square test